Literature DB >> 476303

Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.

H J Cohen, H R Silberman, W E Larsen, L Johnson, A A Bartolucci, J R Durant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 476303

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.

Authors:  H Gössinger; P Bettelheim; E Neumann; W Hinterberger; K Korninger; H Niessner; I Pabinger-Fasching; K Bauer; K Lechner
Journal:  Blut       Date:  1984-11

Review 2.  Multiple myeloma. New treatment options.

Authors:  L Camba; B G Durie
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

3.  [Analysis of prognostic factors in plasmacytoma].

Authors:  W Gassmann; T Haferlach; N Schmitz; W Kayser; H H Euler; J Drews; H Löffler
Journal:  Klin Wochenschr       Date:  1984-10-01

4.  Prognostic factors and classification in multiple myeloma.

Authors:  J F San Miguel; J Sànchez; M Gonzalez
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

5.  Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; S Brugnatelli; C Tinelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; C Bergonzi; M Giordano; C Delfini; G Nicoletti; E Rinaldi; L Piccinini; D Valentini; E Ascari
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

6.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; O Mora; C Tinelli; D Valentini; S Brugnatelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; M Giordano; C Delfini; G Nicoletti; C Bergonzi; E Rinaldi; L Piccinini; E Ascari
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

7.  Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; S Brugnatelli; O Mora; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; F Alberio
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

8.  Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.

Authors:  S Brugnatelli; A Riccardi; G Ucci; O Mora; L Barbarano; N Piva; L Piccinini; C Bergonzi; A De Paoli; M Di Stasi; E Rinaldi; G Trotti; M Petrini; E Ascari
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.